Lingohr Asset Management GmbH Reduces Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Lingohr Asset Management GmbH has significantly reduced its holdings in Thermo Fisher Scientific Inc. by 90%, leaving it with only 900 shares valued at approximately $365,000.
• Several hedge funds have recently increased or established stakes in Thermo Fisher, with institutional investors now owning 89.23% of the company's stock.
• Wall Street analysts have raised their price targets for Thermo Fisher shares, with Barclays upgrading the rating from "equal weight" to "overweight" and setting a target of $550.00.

Lingohr Asset Management GmbH decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 90.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 900 shares of the medical research company's stock after selling 8,068 shares during the quarter. Lingohr Asset Management GmbH's holdings in Thermo Fisher Scientific were worth $365,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $25,000. CBIZ Investment Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific in the first quarter valued at about $30,000. Finally, Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $6.24 during trading hours on Tuesday, reaching $480.70. The company's stock had a trading volume of 1,799,780 shares, compared to its average volume of 1,482,249. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a market capitalization of $181.52 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 2.53 and a beta of 0.75. The firm's 50 day simple moving average is $469.07 and its 200-day simple moving average is $450.41.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The business's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last 90 days. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on TMO shares. Raymond James Financial restated an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.